AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is currently conducting a Phase 1 clinical study titled An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation. The study aims to assess the safety and initial anti-tumor effects of NT-175, a genetically engineered T cell therapy, in patients with specific solid tumors.
The intervention being tested is NT-175, an autologous T cell therapy product designed to target the TP53 R175H mutation in solid tumors. This biological treatment involves pre-conditioning with chemotherapy, a single infusion of TCR T cells, and post-infusion recombinant interleukin-2.
The study follows a non-randomized, single-group assignment model with no masking, focusing primarily on treatment. It includes dose escalation, disease histology evaluation, and cohort expansion phases to determine the maximum tolerated dose and recommended phase 2 dose.
The study began on July 12, 2023, with an estimated completion date of July 22, 2025. These dates are crucial for tracking progress and anticipating results that could influence AstraZeneca’s strategic decisions.
This study update could positively impact AstraZeneca’s stock performance by showcasing its commitment to innovative cancer treatments. Investors might view this as a competitive edge, especially in the rapidly evolving oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.